U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Vandetanib

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 443913-73-3

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of vandetanib during breastfeeding. Because vandetanib is 90% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 19 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during vandetanib therapy and for 4 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Vandetanib

CAS Registry Number

443913-73-3

Drug Class

  • Breast Feeding
  • Lactation
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Signal Transduction Inhibitors
  • Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500867PMID: 29999926

Views

Related information

Similar articles in PubMed

  • Review Gefitinib.[Drugs and Lactation Database (...]
    Review Gefitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Lapatinib.[Drugs and Lactation Database (...]
    Review Lapatinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Dacomitinib.[Drugs and Lactation Database (...]
    Review Dacomitinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Crizotinib.[Drugs and Lactation Database (...]
    Review Crizotinib.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Gilteritinib.[Drugs and Lactation Database (...]
    Review Gilteritinib.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...